IL6 and triple-negative breast carcinoma: For instance, the immunosuppressive drug tocilizumab not only antagonizes IL-6-STAT3 inflammatory signaling, but also restrains the IL-6-STAT3-NF-kB epigenetic feedback axis, which heralds an exciting therapeutic prospect for triple-negative breast cancer patients (Alraouji et al., 2020).